Sol-Gel Technologies Ltd.

SLGL

Healthcare Biotechnology

Sol-Gel Technologies Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $19.4 million, up 68.0% from fiscal 2024.

Revenue
−96.6%
EPS
−127.1%
Free cash flow
−8.76%

Quarter to June 2026, against a year earlier

61.01 2.00 −3.17%
Market cap
$199.8M
P/E
n/m
Fwd P/E
n/m
Dividend yield
—
F-score
6/9
Net debt / EBITDA
3.2×
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

(29.59%) (23.72%) (2.92%) (40.85%)
Piotroski F-Score
— 4 — 2
ROA
(23.17%) (18.63%) (2.44%) (35.11%)
ROIC
(122.92%) 0.00% 0.00% (6,630.24%)
Return on Tangible Assets
(35.03%) (29.26%) (2.11%) (35.30%)
Average Days of Receivables
189.45 37.05 21.09 144.98
Free Cash Flow per Share
0.00 (7.40) 0.00 (6.50)
Free Cash Flow
— (20.61) — (21.27)
Other line items

Show all line items

Columns are period end dates